Drug resistance interpretation: PR HIVDB 9.5.1 (2023-11-05)

PI Major Mutations: V82A V82A

PI Accessory Mutations: L10F pm - L241 pm - L89V pm

Protease Inhibitors

atazanavir/r (ATV/r) Intermediate Resistance
darunavir/r (DRV/r) Potential Low-Level Resistance
lopinavir/r (LPV/r) High-Level Resistance

PR comments

Major

- . IS4V is a non-polymorphic PI-selected mutation that contributes reduced susceptibility to each of the PIs except DRV.
- . VB2A is a non-polymorphic mutation selected primarily by IDV and LPV. It is associated with reduced susceptibility to LPV and to a lesser extent ATV. It increases DRV susceptibility.

Accessory

- L10F is a common non-polymorphic, PI-selected accessory mutation associated with reduced in vitro susceptibility to LPV and DRV.
- . L24I is a non-polymorphic mutation selected by IDV and LPV. It contributes reduced susceptibility to ATV and LPV.
- . LBSV is a nonpolymorphic accessory mutation weakly selected by each of the PIs. It appears to be minimally associated with reduced PI susceptibility. LB9T is an uncommon non-polymorphic PI-selected mutation selected primarily by ATV.

nul. . .

- K20M/V are uncommonrelatively non-polymorphic PI-selected mutations that have not been well studied.
- A71V/T are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations.

Mutation scoring: PR

HIVDB 9.5.1 (2023-11-05)

HIVDB 9.5.1 (2023-11-05)

urug residance muta	ug resistance mutation scores or Pr.		
Rule	ATV/r ≑	DRV/r 💠	LPV/r ≑
L24I	10	0	10
1547	15	0	15
154V + V82A	10	0	10
V82A	15	0	30
L10F	0	5	5
<u>L89V</u>	0	5	0
Total	50	10	70

Drug resistance interpretation: RT

M41L D67E T69ins V75M L210W T215Y

NNRTI Mutations: Y181C ===

Nucleoside Reverse Transcriptase Inhibitors		Non-nucleoside Reverse Transcriptase Inhibitors	
bacavir (ABC)	High-Level Resistance	doravirine (DOR)	Potential Low-Level Re
idovudine (AZT)	High-Level Resistance	efavirenz (EFV)	Intermediate Resistan
mtricitabine (FTC)	Intermediate Resistance	etravirine (ETR)	Intermediate Resistan
mivudine (3TC)	Intermediate Resistance	nevirapine (NVP)	High-Level Resistance
enofovir (TDF)	High-Level Resistance	rilpivirine (RPV)	Intermediate Resistano

RT comments

NRTI Mutations:

RT Other Mutations:

NRTI

- M41L is a TAM that usually occurs with T215Y. In combination, M41L plus T215Y confer intermediate / high-level resistance to AZT and d4T and contribute to reduced dd1, ABC and TDF susceptibility.
- D67N is a non-polymorphic TAM associated with low-level resistance to AZT. D67G/E/S/T/H are non-polymorphic NRTI-selected mutations that generally occur in viruses with multiple TAMs.
- Amino acid insertions between codons 67 and 70 are by convention assigned to codon 69. Together with TAMs, they are associated with high-level resistance to AZT, ABC and TDF, and intermediate to 3TC and FTC.
- V75T/M/A/S are nonpolymorphic accessory NRTI-selected mutations. They appear to have minimal phenotypic effects on AZT, ABC, and TDF.
- L210W is a TAM that usually occurs in combination with M41L and T215Y. The combination of M41, L210W and T215Y causes high-level resistance to AZT and intermediate resistance to ABC and TDF.
- T215Y/F are TAMs that causes intermediate/high-level resistance to AZT and potentially low-level resistance to ABC and TDF.

NNRTI

- Y181C is a non-polymorphic mutation selected in persons receiving NVP, ETR and RPV. It confers high-level resistance to NVP, intermediate resistance to ETR and RPV, and low-level resistance to EFV. It does not significantly reduce DOR susceptibility.
- This virus is predicted to have intermediate-level reduced susceptibility to RPV. The use of the combination of CAB/RPV should be considered to be contraindicated.

Drug resistance mutation scores of NRTI:

Download CSV ABC

AZT

FTC

3TC

TDF Rule M41L 5 15 0 0 5 M41L + D67E + T215Y 10 10 0 0 10 M41L + L210W M41L + L210W + T215Y 10 10 5 5 10 M41L+T215Y D67E 5 15 0 0 5 T69ins 60 60 30 30 60 5 15 0 0 5 L210W

10 60 0 0 10 T215Y 0 10 0 0 0 V75M Total 130 210 50 50 130

L210W + T215Y

Y181C

Drug resistance mutation scores of NNRTI:

Download CSV DOR : EFV ÷ ETR ≑ NVP ÷ RPV = 60 45 10 30 30

10 10 0 0 10